Europe’s Big Pharma Players Begin Tricky 2022 In Style

Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.  

Tightrope
• Source: Shutterstock

European pharma's first quarter financials have been delivered in a challenging and volatile operating environment, where the war in Ukraine and the impact of COVID-19 continue to have an impact, where inflation is up, as are energy and raw material costs and where political tensions are high.

Nevertheless, the continent's drugmakers delivered healthy growth in Q1. In the UK, AstraZeneca PLC continued to profit from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo